Excellent
Partially Aligned
Patient Risk:
Low
Summary
The AI response claims FDA approval date (July 27, 2019) and that it refers to initial US approval. The provided FDA label excerpts do not include any approval-date information, so the claims cannot be verified against the supplied prescribing information.
Category Scores
Accurate Statements
Slynd (drospirenone) was approved by the U.S. FDA on July 27, 2019.
Not evaluable from the provided label excerpts; no approval-date content was supplied.
The July 27, 2019 date refers to the initial FDA approval for Slynd in the US.
Not evaluable from the provided label excerpts; no approval-date content was supplied.
Unsupported Statements
Slynd (drospirenone) was approved by the U.S. FDA on July 27, 2019.
The supplied prescribing-information excerpts do not contain FDA approval-date information, so support cannot be determined.
The July 27, 2019 date refers to the initial FDA approval for Slynd in the US.
The supplied prescribing-information excerpts do not contain any statement explaining what the date refers to, so support cannot be determined.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims concern regulatory approval date/meaning only and do not affect dosing, contraindications, warnings, or safety instructions based on the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Approval-date claims are not supported or verifiable from the provided label excerpts.
Suggested Improvement
Limit the response to on-label clinical content from the prescribing information excerpts; if mentioning regulatory approval date, cite the exact label section or FDA document containing that date.